Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuyzen DF, Selby B, Fan X, Kang V, Walling J, Tombal B; HERO Study Investigators.
N Engl J Med. 2020 Jun 4;382(23):2187-2196. doi: 10.1056/NEJMoa2004325. Epub 2020 May 29.
A phase 2 study of thalidomide for the treatment of radiation-induced blood-brain barrier injury.
Cheng J, Jiang J, He B, Lin WJ, Li Y, Duan J, Li H, Huang X, Cai J, Xie J, Zhang Z, Yang Y, Xu Y, Hu X, Wu M, Zhuo X, Liu Q, Shi Z, Yu P, Rong X, Ye X, Saw PE, Wu LJ, Simone CB 2nd, Chua MLK, Mai HQ, Tang Y.
Sci Transl Med. 2023 Feb 22;15(684):eabm6543. doi: 10.1126/scitranslmed.abm6543. Epub 2023 Feb 22.
Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial.
Zhang T, Howard L, Koontz BF, Tagawa ST, Nagar H, Bitting RL, Frizzell BA, Nordquist L, Rasmussen J, Riggan C, Reyes M, Davies C, Gray SR, Newman CR, Fernandez E, Ramalingam S, Harrison MR, George DJ, Wu Y, Armstrong AJ.
Eur Urol Oncol. 2025 Apr;8(2):287-295. doi: 10.1016/j.euo.2024.06.013. Epub 2024 Jul 5.
Accelerated hematopoietic recovery with angiotensin-(1-7) after total body radiation.
Rodgers KE, Espinoza T, Roda N, Meeks CJ, Hill C, Louie SG, Dizerega GS.
Int J Radiat Biol. 2012 Jun;88(6):466-76. doi: 10.3109/09553002.2012.676228. Epub 2012 Apr 30.
Nivolumab combined with induction chemotherapy and radiotherapy in nasopharyngeal carcinoma: A multicenter phase 2 PLATINUM trial.
Xu C, Zhou GQ, Li WF, Hu DS, Chen XZ, Lin SJ, Jin F, Huang XQ, Peng G, Huang J, Wu Y, Tao CJ, Li JB, Lin AH, Zhao HY, Hong SB, Huang HL, Tang LL, Peng YL, Shi KF, Chen L, Qi LP, Yang KY, Shen LF, Sun Y, Ma J.
Cancer Cell. 2025 May 12;43(5):925-936.e4. doi: 10.1016/j.ccell.2025.01.014. Epub 2025 Feb 27.
Testosterone recovery after androgen deprivation therapy in localised prostate cancer: Long-term data from two randomised trials.
Nabid A, Carrier N, Vigneault E, Martin AG, Bahary JP, Van Nguyen T, Vavassis P, Vass S, Brassard MA, Bahoric B, Archambault R, Vincent F, Bettahar R, Duclos M, Wilke D, Souhami L.
Radiother Oncol. 2024 Jun;195:110256. doi: 10.1016/j.radonc.2024.110256. Epub 2024 Mar 27.
Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10.
Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, Stein J, Hölscher T, Gut P, Polat B, Hildebrandt G, Müller AC, Putora PM, Papachristofilou A, Schär C, Dal Pra A, Biaggi Rudolf C, Wust P, Aebersold DM, Thalmann GN; Swiss Group for Clinical Cancer Research (SAKK).
Radiother Oncol. 2018 Feb;126(2):257-262. doi: 10.1016/j.radonc.2017.10.025. Epub 2017 Nov 3.
Treatment-Related Adverse Effects in Lung Cancer Patients after Stereotactic Ablative Radiation Therapy.
Morias S, Marcu LG, Short M, Giles E, Potter A, Shepherd J, Gierlach T, Bezak E.
J Oncol. 2018 Oct 4;2018:6483626. doi: 10.1155/2018/6483626. eCollection 2018.
Association of PSA kinetics after testosterone recovery with subsequent recurrence: secondary analysis of a phase III randomized controlled trial.
Roy S, Kishan AU, Morgan SC, Martinka L, Spratt DE, Sun Y, Malone J, Grimes S, Citrin DE, Malone S.
World J Urol. 2023 Dec;41(12):3905-3911. doi: 10.1007/s00345-023-04635-1. Epub 2023 Oct 4.
Late xerostomia after intensity-modulated radiation therapy versus conventional radiotherapy.
Pacholke HD, Amdur RJ, Morris CG, Li JG, Dempsey JF, Hinerman RW, Mendenhall WM.
Am J Clin Oncol. 2005 Aug;28(4):351-8. doi: 10.1097/01.coc.0000158826.88179.75.
